The most up-to-date reporting and breakthroughs in anal cancer and HPV research, and the HPV and Anal Cancer Foundation’s latest activities and events.
Dear Friend of ACF, We want you be the first to know that, for the first time in decades, therapeutic options for anal cancer leapt forward. Results from a study funded showed that metastatic anal cancer patients had an enormous response rate (24%) to a new immunotherapy compound called Nivolumab. Further, the drug was well tolerated. Lancet,… read more
What a year this was! 2016 rang in the HPV and Anal Cancer Foundation’s most exciting advances yet This year, your support allowed us to advance research for a cure, contribute to patient and provider education, and fight for improved models of prevention, care and treatment. The highlights included features in Newsweek and the American Cancer Society,… read more
On Sunday, November 13th the International Anal Neoplasia Society (IANS) hosted a panel of anal cancer thrivers, entitled Thrivers In Action. The panel focused on what people who have experienced anal cancer are currently doing to “pay it forward” for other patients and families. The panel was moderated by Justine Almada, Co-Founder and Executive Director… read more